![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Tuesday, September 06, 2022 7:35:33 AM
6:33 am ET September 6, 2022 (Dow Jones) Print
By Dean Seal
Iveric Bio Inc. said Tuesday that a second Phase 3 clinical trial for its geographic atrophy treatment Zimura met its primary endpoint with statistical significance and a favorable safety profile.
The biopharmaceutical company said the two trials have shown a significant reduction in the rate of geographic atrophy progression at the 12-month endpoint.
Iveric said it plans to submit a new drug application for Zimura by the end of the first quarter of 2023.
Shares soared 42% to $13.38 in premarket trading.
ISEE
New York Yankees and Duke Basketball
Recent ISEE News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:49:05 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM